Perrigo Gets "Wake-Up Call" In FDA Warning Letter
This article was originally published in The Tan Sheet
Executive Summary
Perrigo prioritized correcting manufacturing problems that drew an FDA warning, advising the firm to prevent human errors with tighter quality control, according to CEO Joseph Papa
You may also be interested in...
Perrigo Sales Reach Record Highs Despite Manufacturing Restrictions
Acquisitions and new products helped Perrigo grow quarterly revenue 23% to $718 million, despite manufacturing restraints related to an FDA warning letter.
Perrigo Sales Reach Record Highs Despite Manufacturing Restrictions
Acquisitions and new products helped Perrigo grow quarterly revenue 23% to $718 million, despite manufacturing restraints related to an FDA warning letter.
Perrigo Sales Reach Record Highs Despite Manufacturing Restrictions
Acquisitions and new products helped Perrigo grow quarterly revenue 23% to $718 million, despite manufacturing restraints related to an FDA warning letter.